Communications Biology (Jun 2021)
Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells
- Laetitia Seguin,
- Soline Odouard,
- Francesca Corlazzoli,
- Sarah Al Haddad,
- Laurine Moindrot,
- Marta Calvo Tardón,
- Mayra Yebra,
- Alexey Koval,
- Eliana Marinari,
- Viviane Bes,
- Alexandre Guérin,
- Mathilde Allard,
- Sten Ilmjärv,
- Vladimir L. Katanaev,
- Paul R. Walker,
- Karl-Heinz Krause,
- Valérie Dutoit,
- Jann N. Sarkaria,
- Pierre-Yves Dietrich,
- Érika Cosset
Affiliations
- Laetitia Seguin
- University Côte d’Azur, CNRS UMR7284, INSERM U1081, Institute for Research on Cancer and Aging (IRCAN)
- Soline Odouard
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva
- Francesca Corlazzoli
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva
- Sarah Al Haddad
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva
- Laurine Moindrot
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva
- Marta Calvo Tardón
- Laboratory of Immunobiology of brain tumors, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, and University of Geneva
- Mayra Yebra
- Department of Surgery, Moores Cancer Center, University of California San Diego
- Alexey Koval
- Department of Cell Physiology and Metabolism, Medical School, University of Geneva
- Eliana Marinari
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva
- Viviane Bes
- Laboratory of Immunobiology of brain tumors, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, and University of Geneva
- Alexandre Guérin
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva
- Mathilde Allard
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva
- Sten Ilmjärv
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva
- Vladimir L. Katanaev
- Department of Cell Physiology and Metabolism, Medical School, University of Geneva
- Paul R. Walker
- Laboratory of Immunobiology of brain tumors, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, and University of Geneva
- Karl-Heinz Krause
- Department of Pathology and Immunology, Medical School, University of Geneva, Geneva
- Valérie Dutoit
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva
- Jann N. Sarkaria
- Department of Radiation Oncology, Mayo Clinic
- Pierre-Yves Dietrich
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva
- Érika Cosset
- Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva
- DOI
- https://doi.org/10.1038/s42003-021-02258-z
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 17
Abstract
Seguin et al demonstrated in glioblastoma patient-derived stem cells that a subset of glioblastoma tumours is dependent on macropinocytosis mediated survival through a Galectin-3/RAB10/beta 1 integrin axis. They used both genetic and pharmacologic inhibition of Galectin-3 in vivo and in vitro to identify underlying mechanisms and define a Galectin-3/macropinocytosis molecular signature, which could inform the development of anti-tumour therapeutic strategies.
